All In Biotech

NDA 019258 · Ecolab

Cida-Stat

Chlorhexidine Gluconate · Topical

Last checked: Nov 19, 2026Latest source record: Jan 10, 2018 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1986

Jul 22, 1986

Approved uses

1

Original approval plus efficacy supplements

Registered trials

551

112 Phase 3, 30 recruiting

FAERS reports

7,741

6,502 serious, 2,709 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Feb 17, 2026.

Uses surgical hand scrub: significantly reduces the number of microorganisms on the hands and forearms prior to surgery or patient care healthcare personnel handwash: handwash to help reduce bacteria that potentially can cause disease skin wound and general skin cleanser: helps reduce bacteria on the skin

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jul 22, 1986 Original approval · Type 5 - New Formulation or New Manufacturer
2 products under this application
  • CIDA-STAT · CHLORHEXIDINE GLUCONATE 2% · SOLUTION, TOPICAL · Over-the-counter
  • CHG SCRUB · CHLORHEXIDINE GLUCONATE 4% · SOLUTION, TOPICAL · Over-the-counter

Clinical trials

Interventional ClinicalTrials.gov studies with "Chlorhexidine Gluconate" as an intervention, any sponsor and status, largest first.

All 551 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • fatigue1,899
  • joint swelling1,721
  • rash1,695
  • hypersensitivity1,666
  • impaired healing1,631
  • folliculitis1,619
  • weight increased1,608
  • pain1,585
  • stomatitis1,569
  • arthralgia1,554
  • lower respiratory tract infection1,543
  • glossodynia1,530

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200428
200519
200620
200738
200889
200995
2010151
2011160
2012163
201364
201484
2015132
2016244
2017275
2018299
2019311
2020402
2021677
2022604
2023508
20241,323
20251,537
2026518

Recalls

1 FDA enforcement reports for this application.

  • Feb 12, 2016 · Class III · Terminated

    Subpotent drug

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 571 on PubMed

Sponsor: Ecolab · Also marketed as Chg Scrub

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.